GlobeNewswire: RedHill Biopharma Ltd. Contains the last 10 of 526 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:15:28ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/11/16/2127444/0/de/RedHill-Biopharma-h%C3%A4lt-Pr%C3%A4sentation-auf-Deutschem-Eigenkapitalforum-2020.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma hält Präsentation auf Deutschem Eigenkapitalforum 20202020-11-16T14:27:43Z<![CDATA[TEL-AVIV, Israel und RALEIGH, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) („RedHill“ oder das „Unternehmen“), ein spezialisiertes biopharmazeutisches Unternehmen, hat heute bekanntgeben, dass Guy Goldberg, Chief Business Officer von RedHill, am Dienstag, den 17. November 2020, um 9:30 Uhr MEZ auf dem Deutschen Eigenkapitalforum 2020, einer der größten Investorenveranstaltungen in Europa, einen Unternehmensüberblick präsentieren und 1-zu-1-Investorenmeetings abhalten wird.]]>https://www.globenewswire.com/news-release/2020/11/13/2126391/0/en/RedHill-Biopharma-to-Present-at-German-Equity-Forum-2020.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma to Present at German Equity Forum 20202020-11-13T12:00:00Z<![CDATA[TEL AVIV, Israel and RALEIGH, N.C., Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg, RedHill’s Chief Business Officer, will present a corporate overview and host 1-on-1 investor meetings at the German Equity Forum (Deutsches Eigenkapital Forum) 2020, one of Europe’s largest investor events, on Tuesday, November 17, 2020, at 9:30 a.m. CET.]]>https://www.globenewswire.com/news-release/2020/11/12/2125447/0/en/RedHill-Biopharma-Provides-Q3-2020-Results-and-Highlights-Including-300-Talicia-Prescription-Growth.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma Provides Q3/2020 Results and Highlights, Including 300% Talicia Prescription Growth2020-11-12T12:00:00Z<![CDATA[Q3/2020 net revenues of approximately $21 million, with gross profit of $10.6 million, or approximately 51%, up from $6.7 million and approximately 32% in Q2/2020--Strong growth for Talicia® with approximately 300% quarter-over-quarter prescription growth and rapid expansion of the prescriber base; Talicia achieved national coverage for 167 million lives since launch, with additional coverage expected--Two consecutive quarters of Movantik® prescription (TRx) growth, reversing the trend of prescription decline prior to RedHill acquisition--Opaganib’s COVID-19 global Phase 2/3 study advancing rapidly with nearly 50% of patients enrolled and U.S. Phase 2 study over 90% enrolled; Initiated manufacturing ramp-up in preparation for potential emergency use applications as early as Q1/2021--Commencing Phase 3 study with RHB-204 for first-line treatment of pulmonary NTM infections--Cash balance of approximately $51 million as of September 30, 2020--Management to host webcast today, at 8:30 a.m. EST]]>https://www.globenewswire.com/news-release/2020/11/05/2120910/0/en/RedHill-Biopharma-to-Host-Third-Quarter-Financial-Results-and-Business-Highlights-Webcast-on-November-12-2020.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma to Host Third Quarter Financial Results and Business Highlights Webcast on November 12, 20202020-11-05T12:00:00Z<![CDATA[TEL AVIV, Israel and RALEIGH, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, November 12, 2020.]]>https://www.globenewswire.com/news-release/2020/11/04/2120248/0/en/RedHill-Biopharma-Receives-U-S-Patent-Allowance-Covering-Opaganib-and-RHB-107-Combination.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma Receives U.S. Patent Allowance Covering Opaganib and RHB-107 Combination2020-11-04T15:30:00Z<![CDATA[Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036]]>https://www.globenewswire.com/news-release/2020/10/26/2114368/0/en/RedHill-Biopharma-Presents-New-Data-from-Talicia-s-Phase-3-Studies-at-ACG-2020-Focused-on-Achieving-Successful-First-Line-Treatment-in-H-pylori-Eradication.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma Presents New Data from Talicia®’s Phase 3 Studies at ACG 2020 Focused on Achieving Successful First-Line Treatment in H. pylori Eradication2020-10-26T13:00:00Z<![CDATA[H. pylori eradication rates with clarithromycin-based triple therapy were found to be predictably low in the Phase 3 trial, with antibiotic resistance a contributing factor. Despite declining efficacy, physicians are still prescribing these regimens counter to ACG guidelines, which advocate for using first-line regimens that provide the highest likelihood of eradication success--Talicia’s efficacy in the Phase 3 study was unaffected by patient body mass index (BMI), while published data suggest that BMI may be associated with the failure of clarithromycin-based H. pylori treatments, further supporting the use of Talicia as a first-line therapy in all populations--Talicia is the first and only FDA-approved rifabutin-based therapy for the treatment of H. pylori infection, designed as a first-line option to address the high and growing resistance of H. pylori to commonly used antibiotics]]>https://www.globenewswire.com/news-release/2020/10/15/2108873/0/ru/RedHill-Biopharma-%D0%BE%D0%B1%D1%8A%D1%8F%D0%B2%D0%BB%D1%8F%D0%B5%D1%82-%D0%BF%D0%B0%D1%80%D1%82%D0%BD%D0%B5%D1%80%D0%BE%D0%B2-%D0%B4%D0%BB%D1%8F-%D1%80%D0%B0%D1%81%D1%88%D0%B8%D1%80%D0%B5%D0%BD%D0%B8%D1%8F-%D0%BF%D1%80%D0%BE%D0%B8%D0%B7%D0%B2%D0%BE%D0%B4%D1%81%D1%82%D0%B2%D0%B0-Opaganib-%D0%BA%D0%B0%D0%BA-%D0%BF%D0%BE%D1%82%D0%B5%D0%BD%D1%86%D0%B8%D0%B0%D0%BB%D1%8C%D0%BD%D0%BE%D0%B3%D0%BE-%D1%81%D1%80%D0%B5%D0%B4%D1%81%D1%82%D0%B2%D0%B0-%D1%82%D0%B5%D1%80%D0%B0%D0%BF%D0%B8%D0%B8-%D0%B4%D0%BB%D1%8F-%D0%BB%D0%B5%D1%87%D0%B5%D0%BD%D0%B8%D1%8F-COVID-19.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma объявляет партнеров для расширения производства Opaganib как потенциального средства терапии для лечения COVID-192020-10-15T05:46:12Z<![CDATA[Сотрудничество с европейскими и канадскими поставщиками для крупномасштабного наращивания производства opaganib еще больше укрепляет производственные возможности и мощности в рамках подготовки к потенциальным применениям в чрезвычайных ситуациях.--Включение opaganib в глобальное исследование COVID-19 фазы 2/3 быстро увеличивается после одобрения в 6 странах.--Завершается набор в исследование фазы 2 COVID-19 в США с применением opaganib, которое недавно прошло второй обзор независимого комитета]]>https://www.globenewswire.com/news-release/2020/10/15/2108850/0/fr/RedHill-Biopharma-annonce-des-partenariats-visant-%C3%A0-augmenter-la-fabrication-de-l-opaganib-candidat-th%C3%A9rapeutique-pour-le-traitement-du-COVID-19.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma annonce des partenariats visant à augmenter la fabrication de l'opaganib, candidat thérapeutique pour le traitement du COVID-192020-10-15T05:00:00Z<![CDATA[Les collaborations avec des fournisseurs européens et canadiens pour une montée en puissance à grande échelle de la fabrication de l'opaganib renforcent davantage les capacités de fabrication, en préparation d'éventuelles demandes d'utilisation d'urgence-- Le recrutement dans l'étude de phase 2/3 sur le traitement du COVID-19 avec l'opaganib avance rapidement suite aux approbations obtenues dans 6 pays--Le recrutement pour l'étude de phase 2 aux États-Unis sur le traitement du COVID-19 avec l'opaganib est presque terminé et a récemment franchi l'étape du deuxième examen du comité indépendant]]>https://www.globenewswire.com/news-release/2020/10/14/2108804/0/zh-hant/RedHill-Biopharma-%E5%AE%A3%E4%BD%88%E5%90%88%E4%BD%9C%E5%A4%A5%E4%BC%B4%E9%97%9C%E4%BF%82-%E4%BB%A5%E6%93%B4%E5%A4%A7-COVID-19-%E6%B2%BB%E7%99%82%E5%80%99%E9%81%B8%E8%97%A5%E7%89%A9-Opaganib-%E7%9A%84%E7%94%9F%E7%94%A2.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma 宣佈合作夥伴關係,以擴大 COVID-19 治療候選藥物 Opaganib 的生產2020-10-14T23:00:00Z<![CDATA[為準備申請緊急使用授權,RedHill Biopharma 與歐洲和加拿大供應商合作以擴大 opaganib 的生產規模,進一步提升製造能力和產能-- 在 6 個國家 / 地區獲批後,使用 opaganib 治療 COVID-19 的全球第 2/3 期研究納入工作正在快速進行--使用 opaganib 治療 COVID-19 的美國第 2 期研究即將完成納入,且最近通過第二次獨立委員會審查]]>https://www.globenewswire.com/news-release/2020/10/14/2108805/0/zh-hans/RedHill-Biopharma%E5%AE%A3%E5%B8%83%E5%90%88%E4%BD%9C%E4%BC%99%E4%BC%B4%E5%85%B3%E7%B3%BB%E4%BB%A5%E6%89%A9%E5%A4%A7%E6%96%B0%E5%86%A0%E8%82%BA%E7%82%8E%E5%80%99%E9%80%89%E8%8D%AF%E7%89%A9opaganib%E7%9A%84%E5%88%B6%E9%80%A0%E8%A7%84%E6%A8%A1.html?f=22&fvtc=4&fvtv=18150RedHill Biopharma宣布合作伙伴关系以扩大新冠肺炎候选药物opaganib的制造规模2020-10-14T23:00:00Z<![CDATA[与欧洲和加拿大供应商就opaganib的大规模增产进行合作进一步加强制造能力和产能,为潜在的紧急用药申请获批做好准备--使用opaganib治疗新冠肺炎全球2/3期研究的患者招募在6个国家予以批准后迅速推进--在美国进行的opaganib治疗新冠肺炎2期研究即将完成患者招募,并于最近通过了独立委员会第二次审查]]>